The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry
Cisplatin and its analogues are widely used as chemotherapeutic agents in clinical practice. After being intravenously administrated, a substantial amount of platinum will bind with proteins in the blood. This binding is vital for the transport, distribution, and metabolism of drugs; however, toxici...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/2/104 |
_version_ | 1797405981577052160 |
---|---|
author | Jingchen Wang Jianmei Tao Shuailong Jia Meiqin Wang Hongliang Jiang Zhifeng Du |
author_facet | Jingchen Wang Jianmei Tao Shuailong Jia Meiqin Wang Hongliang Jiang Zhifeng Du |
author_sort | Jingchen Wang |
collection | DOAJ |
description | Cisplatin and its analogues are widely used as chemotherapeutic agents in clinical practice. After being intravenously administrated, a substantial amount of platinum will bind with proteins in the blood. This binding is vital for the transport, distribution, and metabolism of drugs; however, toxicity can also occur from the irreversible binding between biologically active proteins and platinum drugs. Therefore, it is very important to study the protein-binding behavior of platinum drugs in blood. This review summarizes mass spectrometry-based strategies to identify and quantitate the proteins binding with platinum anticancer drugs in blood, such as offline high-performance liquid chromatography/inductively coupled plasma mass spectrometry (HPLC–ICP-MS) combined with electrospray ionization mass spectrometry (ESI-MS/MS) and multidimensional LC–ESI-MS/MS. The identification of in vivo targets in blood cannot be accomplished without first studying the protein-binding behavior of platinum drugs in vitro; therefore, relevant studies are also summarized. This knowledge will further our understanding of the pharmacokinetics and toxicity of platinum anticancer drugs, and it will be beneficial for the rational design of metal-based anticancer drugs. |
first_indexed | 2024-03-09T03:19:08Z |
format | Article |
id | doaj.art-a8c74511a2c94a9491abc4ff42207f15 |
institution | Directory Open Access Journal |
issn | 1424-8247 |
language | English |
last_indexed | 2024-03-09T03:19:08Z |
publishDate | 2021-01-01 |
publisher | MDPI AG |
record_format | Article |
series | Pharmaceuticals |
spelling | doaj.art-a8c74511a2c94a9491abc4ff42207f152023-12-03T15:14:24ZengMDPI AGPharmaceuticals1424-82472021-01-0114210410.3390/ph14020104The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass SpectrometryJingchen Wang0Jianmei Tao1Shuailong Jia2Meiqin Wang3Hongliang Jiang4Zhifeng Du5School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, ChinaSchool of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, ChinaSchool of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, ChinaSchool of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, ChinaSchool of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, ChinaSchool of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, ChinaCisplatin and its analogues are widely used as chemotherapeutic agents in clinical practice. After being intravenously administrated, a substantial amount of platinum will bind with proteins in the blood. This binding is vital for the transport, distribution, and metabolism of drugs; however, toxicity can also occur from the irreversible binding between biologically active proteins and platinum drugs. Therefore, it is very important to study the protein-binding behavior of platinum drugs in blood. This review summarizes mass spectrometry-based strategies to identify and quantitate the proteins binding with platinum anticancer drugs in blood, such as offline high-performance liquid chromatography/inductively coupled plasma mass spectrometry (HPLC–ICP-MS) combined with electrospray ionization mass spectrometry (ESI-MS/MS) and multidimensional LC–ESI-MS/MS. The identification of in vivo targets in blood cannot be accomplished without first studying the protein-binding behavior of platinum drugs in vitro; therefore, relevant studies are also summarized. This knowledge will further our understanding of the pharmacokinetics and toxicity of platinum anticancer drugs, and it will be beneficial for the rational design of metal-based anticancer drugs.https://www.mdpi.com/1424-8247/14/2/104platinumanticancer drugsbloodbinding proteinsmass spectrometry |
spellingShingle | Jingchen Wang Jianmei Tao Shuailong Jia Meiqin Wang Hongliang Jiang Zhifeng Du The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry Pharmaceuticals platinum anticancer drugs blood binding proteins mass spectrometry |
title | The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry |
title_full | The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry |
title_fullStr | The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry |
title_full_unstemmed | The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry |
title_short | The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry |
title_sort | protein binding behavior of platinum anticancer drugs in blood revealed by mass spectrometry |
topic | platinum anticancer drugs blood binding proteins mass spectrometry |
url | https://www.mdpi.com/1424-8247/14/2/104 |
work_keys_str_mv | AT jingchenwang theproteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT jianmeitao theproteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT shuailongjia theproteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT meiqinwang theproteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT hongliangjiang theproteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT zhifengdu theproteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT jingchenwang proteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT jianmeitao proteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT shuailongjia proteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT meiqinwang proteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT hongliangjiang proteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry AT zhifengdu proteinbindingbehaviorofplatinumanticancerdrugsinbloodrevealedbymassspectrometry |